Statistical Considerations for Design and Analysis of Bridging Studies

By Harry Yang, Timothy Shofield  

Introduction In biological product development, a wide range of analytical methods are used to ensure product quality throughout the lifecycle of a product. These methods include tests for product identity, purity, concentration, and potency. As the product progresses through early-stage to late-stage development, and ultimately manufacturing, a parallel effort is made to improve the analytical methods, taking advantage of emerging state-of-art analytical technologies and increased understanding of drug mechanism of action. Bridging studies should be conducted to demonstrate that when compared...

This content is only available to IVT members.

Get help maintaining your knowledge in GMP - Variation & Statistics. Read More!

If you are already a member and you do not have access to this article, upgrade your membership. Need help? Read our FAQs.

Tags:
GMP - Variation & Statistics, JVT

Harry Yang
Harry Yang, Ph.D., Senior Director, head of Non-Clinical Biostatistics Group at MedImmune, the global biologics arm of AstraZeneca headquartered in Gaithersburg, Maryland. The group provides statistical support to...

View Author Bio

Timothy Shofield
Timothy Shofield is a Senior Fellow at MedImmune.

View Author Bio

Source URL: http://www.ivtnetwork.com/article/statistical-considerations-design-and-analysis-bridging-studies